仙琚制药
(002332)
| 流通市值：85.66亿 | | | 总市值：86.06亿 |
| 流通股本：9.85亿 | | | 总股本：9.89亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 918,349,166.84 | 3,758,969,165.42 | 2,825,580,737.5 | 1,869,227,375.54 |
| 营业收入 | 918,349,166.84 | 3,758,969,165.42 | 2,825,580,737.5 | 1,869,227,375.54 |
| 二、营业总成本 | 810,954,601.33 | 3,292,197,358.83 | 2,381,807,724.46 | 1,540,784,233.35 |
| 营业成本 | 372,237,605.31 | 1,458,967,954.93 | 1,065,002,042 | 688,613,769.15 |
| 税金及附加 | 7,161,090.74 | 39,503,429.87 | 27,667,995.55 | 18,924,065.74 |
| 销售费用 | 284,470,963.24 | 1,180,436,455.03 | 841,424,817.23 | 547,773,849.8 |
| 管理费用 | 74,372,386.44 | 317,390,102.15 | 254,557,160.59 | 164,426,361.26 |
| 研发费用 | 69,002,590.89 | 303,747,966.62 | 198,415,154.74 | 125,931,193.93 |
| 财务费用 | 3,709,964.71 | -7,848,549.77 | -5,259,445.65 | -4,885,006.53 |
| 其中:利息费用 | 725,412.82 | 4,644,527.08 | 3,223,366.44 | 1,636,833.05 |
| 其中:利息收入 | 2,323,060.26 | 16,726,364.65 | 12,685,528.25 | 9,371,653.97 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -5,571,904.07 | -26,411,420.79 | -12,250,725.16 | -9,616,902.06 |
| 资产处置收益 | -114,585.32 | 46,299,441.47 | 46,269,885.05 | 46,212,235.3 |
| 资产减值损失(新) | - | -38,213,637.37 | -24,217,765.45 | -24,235,367.74 |
| 信用减值损失(新) | -2,067,376.63 | -7,289,272.83 | -5,846,584.09 | -4,916,682.98 |
| 其他收益 | 9,791,499.58 | 31,201,581.31 | 16,374,580.92 | 11,154,968.28 |
| 四、营业利润 | 109,432,199.07 | 472,358,498.38 | 464,102,404.31 | 347,041,392.99 |
| 加:营业外收入 | 9,253.7 | 72,978,072.14 | 226,490.17 | 365,716.9 |
| 减:营业外支出 | 1,138,779.56 | 9,495,517.39 | 6,978,308.19 | 4,077,889.25 |
| 五、利润总额 | 108,302,673.21 | 535,841,053.13 | 457,350,586.29 | 343,329,220.64 |
| 减:所得税费用 | 17,934,135.59 | 83,237,392.57 | 61,480,597.74 | 47,232,563.3 |
| 六、净利润 | 90,368,537.62 | 452,603,660.56 | 395,869,988.55 | 296,096,657.34 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 90,368,537.62 | 452,603,660.56 | 395,869,988.55 | 296,096,657.34 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 93,886,296.97 | 449,640,395.37 | 406,684,611.31 | 308,268,256.98 |
| 少数股东损益 | -3,517,759.35 | 2,963,265.19 | -10,814,622.76 | -12,171,599.64 |
| 扣除非经常损益后的净利润 | 90,112,023.4 | 348,698,522.73 | 363,232,546.08 | 266,773,796.21 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.09 | 0.45 | 0.41 | 0.31 |
| (二)稀释每股收益 | 0.09 | 0.45 | 0.41 | 0.31 |
| 八、其他综合收益 | -50,090,940.43 | 127,106,783.52 | 137,744,065.47 | 149,107,625.78 |
| 归属于母公司股东的其他综合收益 | -50,090,940.43 | 127,106,783.52 | 137,744,065.47 | 149,107,625.78 |
| 九、综合收益总额 | 40,277,597.19 | 579,710,444.08 | 533,614,054.02 | 445,204,283.12 |
| 归属于母公司股东的综合收益总额 | 43,795,356.54 | 576,747,178.89 | 544,428,676.78 | 457,375,882.76 |
| 归属于少数股东的综合收益总额 | -3,517,759.35 | 2,963,265.19 | -10,814,622.76 | -12,171,599.64 |
| 公告日期 | 2026-04-28 | 2026-04-23 | 2025-10-28 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |